1
/
of
0
FDA Adverse Event Summary for Tums, Tums Ultra, Tislelizumab, Capivasertib, Foscarbidopa/Foslevodopa, and Infliximab-dyyb (Jan–Mar 2025)
FDA Adverse Event Summary for Tums, Tums Ultra, Tislelizumab, Capivasertib, Foscarbidopa/Foslevodopa, and Infliximab-dyyb (Jan–Mar 2025)
Regular price
$69.00 USD
Regular price
Sale price
$69.00 USD
Unit price
/
per
Original Request: Please provide me with data summarizing reports of adverse events associated with the following drugs between Jan. 1, 2025 and March 18, 2025: Tums and Tums Ultra, tislelizumab, capivasertib, foscarbidopa/foslevodopa, and infliximab-dyyb.
Tags: Pharma, Adverse Event, 2025
Tags: Pharma, Adverse Event, 2025
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details